Episode

Alcon and Lensar Call Off Merger

Podcast
Eyewire News: The Podcast
Published
Mar 18, 2026
Duration seconds
382
Processing state
not_requested
Canonical source
https://traffic.megaphone.fm/BMCL9514359622.mp3?updated=1773860036
Audio
https://traffic.megaphone.fm/BMCL9514359622.mp3?updated=1773860036
JSON
/v1/public/podcasts/eyewire-news-the-podcast-7055536/episodes/alcon-and-lensar-call-off-merger
Markdown
/podcast/eyewire-news-the-podcast-7055536/alcon-and-lensar-call-off-merger.md

Actions

  • POST https://stenobird.com/v1/public/podcasts/eyewire-news-the-podcast-7055536/episodes/alcon-and-lensar-call-off-merger/transcription-requests
    Idempotently request low-priority transcript generation for this episode.
  • GET https://stenobird.com/podcast/eyewire-news-the-podcast-7055536/alcon-and-lensar-call-off-merger.md
    Read the agent-friendly Markdown representation of this episode resource.

Summary

Alcon and Lensar provide a major update to their proposed merger; the latest IOL on Johnson & Johnson’s Tecnis platform receives FDA approval; and the FDA issues another CRL to Aldeyra Therapeutics for its investigational dry eye drug reproxalap. Learn more about your ad choices. Visit megaphone.fm/adchoices